Mercer Global Advisors
ESPR

Mercer Global Advisors’s Esperion Therapeutics ESPR Stock Holding History

Mercer Global Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$790 Buy
+250
New +$699 ﹤0.01% 5767

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mercer Global Advisors's ESPR Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 250 shares worth $790. The stake represents ﹤0.01% of the portfolio and ranks #5767 among its holdings.

130 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Mercer Global Advisors held 250 shares of Esperion Therapeutics worth $790 as of Q2 2026.
  • Esperion Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5767 holding.
  • 130 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.